drugset / Trial / NCT06487221
Avutometinib and Defactinib in Diffuse Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if the combination study treatment with avutometinib and defactinib will prolong life in participants, is effective in decreasing the size of the tumor(s), and if it is safe in subjects with diffuse-type stomach cancer.
Timeline
- Start
- 2024-10-28
- Primary completion
- 2028-11-30
- Completion
- 2029-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avutometinib | Small molecule | 3.2 mg | Oral |
| Subject | Defactinib | Small molecule | 200 mg | Oral |